This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBLI Cleveland BioLabs (CBLI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Cleveland BioLabs Stock (NASDAQ:CBLI) 30 days 90 days 365 days Advanced Chart Get Cleveland BioLabs alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.20▼$4.3452-Week Range N/AVolume1,708 shsAverage Volume271,922 shsMarket Capitalization$5 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO. Read More Receive CBLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter. Email Address CBLI Stock News HeadlinesEagles' Tyrie Cleveland, Moro Ojomo carted off field after suffering neck injuriesSeptember 2, 2023 | usatoday.comCleveland Construction NewsJuly 28, 2023 | bizjournals.comBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…July 3 at 2:00 AM | Crypto 101 Media (Ad)Best Hospitals in Cleveland, OHJune 28, 2023 | health.usnews.comCleveland EMS worker who went missing for 6 days remains hospitalized after found safeMay 22, 2023 | abcnews.go.comCleveland Clinic Rehabilitation HospitalMay 17, 2023 | health.usnews.comGetting Around ClevelandApril 18, 2023 | travel.usnews.comCleveland BioLabs Stock Gaps Down On Today's Open (CBLI)March 31, 2023 | thestreet.comSee More Headlines CBLI Stock Analysis - Frequently Asked Questions How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share for the quarter. The biotechnology company had revenue of $0.16 million for the quarter. What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Novavax (NVAX) and BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings5/15/2020Today7/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CBLI CIK1318641 Webwww.cbiolabs.com Phone(888) 613-8802FaxN/AEmployees4Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.84% Return on Assets-31.29% Debt Debt-to-Equity RatioN/A Current Ratio45.93 Quick Ratio45.93 Sales & Book Value Annual Sales$260 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / BookN/AMiscellaneous Outstanding Shares15,479,000Free FloatN/AMarket Cap$5 thousand OptionableNot Optionable Beta0.70 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CBLI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
